Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 6Unknown 3Terminated 2Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 73OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Melanoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Immunotherapy × Clear all
NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT06974110 2026-04-15

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

MOMA Therapeutics

Phase 1 Recruiting
132 enrolled
GastrointestinalGynecologic

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡